• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Pangea Biomed’s ENLIGHT-DP Predicts Cancer Treatment Response from Simple Scans

by Fred Pennic 07/03/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Pangea Biomed, a leader in precision oncology, announced a significant breakthrough in its ENLIGHT cancer response predictor. A new study published in Nature Cancer demonstrates the effectiveness of their ENLIGHT-DP platform, revealing its ability to predict cancer treatment response across various types and drugs using only routine pathology slides.

– While these findings are promising, further validation and testing are planned for regulatory approval.

Challenges in Personalized Cancer Treatment

Current methods for predicting cancer treatment response from tissue samples often require large datasets of matched images and treatment outcomes for each specific drug. This data scarcity limits their applicability and generalizability.

ENLIGHT-DP: A Versatile Solution

The ENLIGHT-DP method tackles these limitations with a two-step approach:

  1. DeepPT: This deep learning technology predicts gene expression from standard H&E stained pathology slides.
  2. ENLIGHT: This utilizes the inferred gene expression data to predict patient response to specific treatments.

Key Advantages of ENLIGHT-DP

  • Bypasses Data Limitations: ENLIGHT-DP eliminates the need for extensive, drug-specific training data, making it broadly applicable.
  • Improved Accuracy: Studies show the odds of a successful treatment response more than doubled using ENLIGHT-DP recommendations (odds ratio: 2.28).
  • Wider Applicability: The method works across various cancers and treatment options, potentially transforming clinical practices.

“ENLIGHT-DP bypasses the data availability limitations that hinder existing approaches by eliminating the need for dedicated training on new cohorts for each drug treatment,” said Ranit Aharonov, Pangea’s CTO, who co-led the study. “This versatile solution can be applied across various cancer types and therapies, potentially transforming clinical practices and significantly improving patient outcomes.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Cancer Diagnostics, Oncology Platform

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Digital Health Funding Q3 2025: Choppy Undercurrents Beneath a Steady Surface

Featured Interview

ConcertAI VP Shares View on AI Hallucinations and the Fabricated Data Crisis in Scientific Publishing

Most-Read

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

KLAS Report: Epic's Native Ambient Speech Tool Reshapes Customer AI Strategies

KLAS Report: Epic’s Native Ambient Speech Tool Reshapes Customer AI Strategies

Epic Unveils MyChart Central and New APIs to Advance Interoperability at Open@Epic

Epic Outlines Roadmap for Next-Generation Data Sharing at Open@Epic

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

Oracle Confirms Layoffs in Kansas City

Oracle Confirms Layoffs in Kansas City

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Optain Health Secures $26M to Advance AI-Powered Retinal Screening

Optain Health Secures $26M for AI-Powered Retinal Screening

Sutter Health and Epic Launch "Sutter Sync" to Optimize Remote Chronic Care

Sutter Health and Epic Launch “Sutter Sync” to Optimize Remote Chronic Care

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |